XML 61 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727
Combined Statement of Stockholders' Equity - USD ($)
Total
Vyrix Pharmaceuticals [Member]
Luoxis Diagnostics [Member]
Common Stock [Member]
Common Stock [Member]
Vyrix Pharmaceuticals [Member]
Common Stock [Member]
Luoxis Diagnostics [Member]
Parent [Member]
Parent [Member]
Vyrix Pharmaceuticals [Member]
Parent [Member]
Luoxis Diagnostics [Member]
Additional Paid in Capital [Member]
Additional Paid in Capital [Member]
Vyrix Pharmaceuticals [Member]
Additional Paid in Capital [Member]
Luoxis Diagnostics [Member]
Accumulated Deficit [Member]
Beginning Balance at Jun. 30, 2012 $ 5,738,033           $ 7,974,768           $ (2,236,735)
Investment from Ampio in subsidiary   $ 2,320,011 $ 248,426         $ 2,320,011 $ 176,736     $ 71,690  
Beginning Balance, shares at Jun. 30, 2012       0                  
Stock-based compensation 316,949                 $ 316,949      
Net loss (2,842,512)                       (2,842,512)
Issuance of common stock of Luoxis in exchange for offering costs of $985,274 (Note 6)     3,980,290     $ 103           3,980,187  
Issuance of common stock of Luoxis in exchange for offering costs of $985,274 (Note 6), shares           1,026,118              
Issuance of common stock of Luoxis for cash net of patents     $ 50,000     $ 1           49,999  
Issuance of common stock of Luoxis for cash net of patents, shares           11,028              
Issuance of Luoxis common stock           $ 440           $ (440)  
Issuance of Luoxis common stock, shares           4,400,012              
Ending Balance at Jun. 30, 2013 9,811,197     $ 544     $ 10,471,515     4,418,385     (5,079,247)
Ending Balance, shares at Jun. 30, 2013       5,437,158                  
Investment from Ampio in subsidiary   $ 637,210           637,210          
Issuance of common stock in exchange for Vyrix Aquired Assets         $ 246     $ (11,108,725)     $ 11,108,479    
Issuance of common stock in exchange for Vyrix Aquired Assets, shares         2,464,268                
Stock-based compensation 499,690                 499,690      
Stock-based compensation (unaudited), shares       0                  
Net loss (5,578,690)                       (5,578,690)
Ending Balance at Jun. 30, 2014 5,369,407     $ 790           16,026,554     (10,657,937)
Ending Balance, shares at Jun. 30, 2014       7,901,426                  
Stock-based compensation (unaudited) 749,809                 749,809      
Stock-based compensation (unaudited), shares       0                  
Net loss (5,567,960)                       (5,567,960)
Ending Balance at Mar. 31, 2015 $ 551,256     $ 790           $ 16,776,363     $ (16,225,897)
Ending Balance, shares at Mar. 31, 2015       7,901,426